# Johnson & Johnson Stock Analysis: Steady Growth & Recent FDA Approval Boost Investor Confidence
Discover why Johnson & Johnson (JNJ) remains a healthcare heavyweight with its current stock performance around $186.67, strong analyst upgrades, and recent FDA approval success. This episode breaks down JNJ's market position following its 2023 consumer health spinoff, examining its attractive P/E ratio of 18, reliable 2.7% dividend yield, and why UBS analysts have raised their price target to $214. Learn about JNJ's technical indicators suggesting long-term stability, trading patterns, and why both institutional and retail investors continue to view this pharmaceutical giant as a defensive investment choice despite modest short-term volatility. Perfect for investors seeking insights on blue-chip healthcare stocks with proven innovation pipelines and consistent dividend performance.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
